Pliant Therapeutics has been granted a patent for compounds that act as aVß6 integrin inhibitors, useful in treating fibrotic diseases like idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. The method involves administering the compound to individuals in need. GlobalData’s report on Pliant Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Pliant Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Pliant Therapeutics's grant share as of January 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of fibrotic diseases using compound of formula (a)
A recently granted patent (Publication Number: US11858931B2) discloses a method for treating fibrotic diseases in individuals by administering a specific compound of formula (A). The method involves inhibiting aVß6 integrin and TGFß activation in cells by administering the compound or its pharmaceutically acceptable salt. The patent also covers the modulation of integrins in subjects, particularly those at risk of fibrotic diseases such as pulmonary fibrosis, liver fibrosis, and primary sclerosing cholangitis, by administering the compound to inhibit aVß1 and aVß6 integrins, thereby treating the underlying condition.
Furthermore, the patent details the administration of the compound to individuals with specific fibrotic diseases like NASH, IPF, and PSC, targeting the inhibition of aVß1 or aVß6 integrins based on the disease. The method aims to modulate TGFß activation in cells, particularly in fibroblasts and epithelial cells, to treat various tissues affected by elevated levels of TGFß activation, aVß1 integrin activity, or aVß6 integrin activity. The patent also includes specific compounds within the formula (A) category for treating fibrotic diseases, emphasizing the use of pharmaceutical compositions comprising the compound and a suitable carrier or excipient for effective treatment.
To know more about GlobalData’s detailed insights on Pliant Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
